.png/:/rs=h:101,cg:true,m/qt=q:100/ll)
1. Biotech Australia Feasibility
Still weighing whether Australia should be part of your portfolio? Our rapid assessments give you clarity before you commit.
Services:
- Evidence Gap Assessment – Stress-test your global data against Australian payer expectations to avoid costly rejections.
- KOL Mapping – Identify the right Australian experts and stakeholders to build early advocacy.
- Market Entry Risk Snapshot – Flag regulatory, evidence, and reimbursement risks before you invest.
2. Australian Market Entry Pathway
Once you’ve decided on Australia, we help you shape the path to market and avoid the pitfalls that stall launches.
Serices:
- Market Research – Understand treatment landscape, prescriber beliefs, and pricing dynamics.
- KOL Engagement Accelerator – build Australian KOL networks, establish trusted partnerships with relevant stakeholders, and foster HCP advocacy.
- Advisory Boards – Gain local insights to refine strategy and evidence presentation.
- Payer Submission Strategy – Tailor EU/US dossiers to Australia’s landscape, aligning on clinical need, target population, comparator, cost-effectiveness, and real-world evidence.
3. Comprehensive Launch Excellence in Australia
For complex or rare-disease launches, you need more than targeted projects. Our comprehensive program delivers full end-to-end launch readiness — covering regulatory and reimbursement strategies, advocacy, and market shaping.
Services:
- Australian Launch Strategy Overhaul – From evidence adaptation to funding readiness, KOL engagement, compliance, and field force planning.
